(IN BRIEF) BioNTech agreed to buy CureVac in an all-stock deal valuing CureVac at ~$1.25 billion, exchanging each share for $5.46 in BioNTech ADSs—a 55% premium to its recent stock price. The merger, expected to close in 2025, strengthens BioNTech’s … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged 2025 closing, ADSs, Alexander Zehnder, all-stock acquisition, American depositary shares, BioNTech, BNT327, Cancer Immunotherapy, CureVac, delivery formulations, dievini Hopp BioTech, integration plan, KfW, merger premium, mRNA, mRNA manufacturing, oncology strategy, pan-tumor programs, partnership, regulatory approvals, transformational therapies, Tübingen subsidiary, Ugur Sahin
(IN BRIEF) Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older. Pending final approval from the European Commission, the vaccine will … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged BioNTech, COVID-19 vaccine, New York, Omicron KP.2, partnership, Pfizer, safety, sustainability
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) BioNTech and Duality Biologics have announced the commencement of a pivotal Phase 3 trial for BNT323/DB-1303, a next-generation antibody-drug conjugate (ADC) targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in metastatic breast cancer. The trial will enroll … Read the full press release
(IN BRIEF) BioNTech has achieved a significant milestone in expanding mRNA vaccine manufacturing in Africa with the inauguration of its Kigali site, which includes the first manufacturing unit known as BioNTainer. This move is part of BioNTech’s broader efforts to … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Africa, BioNTainer, BioNTech, Dr. Jean Kaseya, H.E. Macky Sall, H.E. Paul Kagame, H.E. Ursula von der Leyen, Hon. Annalena Baerbock, Moussa Faki Mahamat, mRNA Vaccine, Prof. Ugur Sahin, Rwanda, Sierk Poetting, vaccine
(IN BRIEF) BioNTech, a leading biotechnology company, has formalized a multi-year strategic partnership with the State of Victoria in Australia, building upon a prior Letter of Intent established in October 2022. The collaboration aims to strengthen the local mRNA ecosystem … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Australia, BioNTainers, BioNTech, mRNA Ecosystem, partnership, Prof. Ugur Sahin, Sierk Poetting, sustainability, Victoria
(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annaliesa Anderson, BioNTech, Combination Vaccine, Comirnaty, COVID-19, influenza, influenza A, influenza B, mRNA, partnership, Pfizer, Prof. Ugur Sahin, respiratory diseases, SARS-CoV-2 strains, sustainability, wellness
(IN BRIEF) BioNTech SE is set to reveal its financial results for the third quarter of 2023 on November 6th, 2023. The company invites investors and the public to participate in a conference call and webcast at 8:00 a.m. ET … Read the full press release
Posted in Business, Financial, Germany, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged BioNTech, Financial, INNOVATION, investment
(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged BioNTech, BNT211, BNT325, cancer therapy, CAR-T, ESMO Congress 2023, ex-vivo T cell therapies, Prof. Özlem Türeci
(IN BRIEF) BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to develop an mRNA-based vaccine, BNT166, for the prevention of mpox (formerly monkeypox), an infectious disease that can have severe and life-threatening complications. … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Norway, Pharma & Biotech, Science
Tagged BioNTech, BNT166, CEPI, mpox Prevention, mRNA-Based Vaccine, partnership, Prof. Ugur Sahin, Richard Hatchett, sustainability
(IN BRIEF) The European Union Commission has given the green light for the use of the adapted Comirnaty XBB.1.5 COVID-19 vaccine, developed by BioNTech-Pfizer, in Member States’ upcoming fall vaccination campaigns. This marks the third adaptation of the Comirnaty vaccine … Read the full press release
(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The recommendation includes the administration of a single … Read the full press release
Posted in Business, European Union, Germany, Government, Healthcare, Industrial, Management, Marketing, News, Pharma & Biotech, Science
Tagged Albert Bourla, BioNTech, Comirnaty, COVID-19 vaccine, EMA, Omicron XBB.1.5-Adapted, Pfizer, Prof. Ugur Sahin, Tozinameran
(IN BRIEF) BioNTech SE, a biopharmaceutical company, has appointed James Ryan as Chief Legal Officer (CLO) and a member of the Management Board, effective from September 1, 2023. In this role, Ryan will oversee the company’s corporate legal strategy, global … Read the full press release
Posted in Business, Germany, Industrial, Management, News, Pharma & Biotech, Science
Tagged appointment, BioNTech, Chief Legal Officer, Helmut Jeggle, James Ryan, leadership
(IN BRIEF) BioNTech reported its second-quarter 2023 financial results and corporate update, highlighting significant pipeline advancements in oncology with the initiation of BNT316/ONC-392 Phase 3 pivotal trial and positive data updates across multiple technology platforms. The company also prepares for … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Management, News, Pharma & Biotech, Science
Tagged BioNTech, Financial, Jens Holstein, Omicron-Adapted COVID-19 Vaccine, oncology pipeline, partnership, Pfizer, Prof. Ugur Sahin
(IN BRIEF) BioNTech SE has completed the acquisition of InstaDeep Ltd., a prominent AI and ML technology company. The acquisition is part of BioNTech’s strategy to enhance AI-driven drug discovery and develop advanced immunotherapies and vaccines for diseases with significant … Read the full press release
(IN BRIEF) BioNTech and OncoC4 have entered into an exclusive license and collaboration agreement to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392. The candidate aims to delete immunosuppressive T cells in the tumor microenvironment but spare T cells … Read the full press release
Posted in Germany, Management, News, Pharma & Biotech, Science, Technology
Tagged anti-CTLA-4 monoclonal antibody, BioNTech, Germany, ONC-392, OncoC4, Prof. Ugur Sahin, T cells, Yang Liu
Siemens prend la cinquième place du classement des brevets de l’Office européen des brevets Vingtinventions par jour ouvrable au cours de l’exercice 2021 Forte croissance des technologies pour l’Internet Industriel des Objets Le magazine économique américain Fast Company reconnaît Siemens … Read the full press release
Posted in Awards, Business, Electronics & Machinery, Germany, Industrial, Management, News, Technology
Tagged apprentissage automatique, BioNTech, Blockchain, Dr. Roland Busch, fabrication additive, Fast Company, IdO, intelligence artificielle, Office européen des brevets, sécurité des données, Siemens, villes intelligentes
Siemens takes fifth place in European Patent Office’s patent ranking Twentyinventions per working day in fiscal 2021 Strong growth in technologies for the Industrial Internet of Things U.S. business magazine Fast Company recognizes Siemens as one of world’s most innovative … Read the full press release
Posted in Awards, Business, Electronics & Machinery, Germany, Industrial, Management, News, Technology
Tagged additive manufacturing, artificial-intelligence, BioNTech, Blockchain, data security, Dr. Roland Busch, European Patent Office, Fast Company, Inventor of the Year 2021, IoT, Machine Learning, Siemens, Smart Cities
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?